Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR1 | P30989 | 15/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | TSPO | P30536 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | NEK2 | P51955 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3052324 | 0.92 | NTSR1 (0.36) | NTSR1HTR1ATSPOHTR7HRH1 | |
| SCHEMBL3061996 | 0.88 | PDE10A (0.43) | NTSR1HTR1ATSPOHTR7HRH1 | |
| SCHEMBL3049951 | 0.86 | NTSR1 (0.39) | NTSR1HTR1ATSPOHTR7HRH1 | |
| SCHEMBL3042342 | 0.83 | NTSR1 (0.35) | NTSR1HTR1ATSPOHTR7HRH1 | |
| SCHEMBL3055190 | 0.79 | NTSR1 (0.41) | NTSR1HTR1ATSPOHTR7HRH1 | |
| SCHEMBL3060162 | 0.79 | PDE10A (0.44) | NTSR1HTR1ATSPOHTR7HRH1 | |
| SCHEMBL3049677 | 0.79 | HTT (0.38) | NTSR1MAP4K4ALDH1A1NEK2 | |
| SCHEMBL3057287 | 0.79 | HTT (0.39) | NTSR1ALDH1A1NEK2 | |
| SCHEMBL3047040 | 0.77 | PDE10A (0.39) | NTSR1HTR1ATSPOHTR7HRH1 | |
| SCHEMBL3059655 | 0.76 | MAP4K4 (0.41) | MAP4K4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222353-A1 | AMINOPHTHALAZINE DERIVATIVE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2010-09-02 | — | — | US | claimed |
| US-20100222353-A1 | AMINOPHTHALAZINE DERIVATIVE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222353-A1 | AMINOPHTHALAZINE DERIVATIVE COMPOUNDS | PDE12, PDE5A, PDE2A | NTSR1 2789/4885HTR1A 547/4885TSPO 2358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.